Irbesartan-Comp Puren

Hydrochlorothiazide / Irbesartan, the active ingredient in Irbesartan-Comp Puren, is an Angiotensin II receptor blocker; Thiazide diuretic presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure in adult patients with hypertension. GNH USA supplies Irbesartan-Comp Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan-Comp Puren is an antihypertensive agent that acts on the renin‑angiotensin‑aldosterone system and renal sodium handling. - Hypertension: reduces systolic and diastolic blood pressure by vasodilation and decreased plasma volume. - Essential hypertension: improves long‑term cardiovascular risk control in patients with primary high blood pressure. - Hypertension with fluid retention: adds diuretic effect to control edema while lowering pressure.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Elevated blood glucose: modest rise in fasting glucose.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat. - Severe dehydration: excessive fluid loss leading to hypotension. - Hyperkalemia: dangerously high potassium levels. - Acute renal impairment: sudden decline in kidney function. - Anaphylactic reaction: severe allergic response. - Hepatic injury: rare liver enzyme elevations.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: check regularly to avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR. - Electrolyte surveillance: monitor potassium and sodium levels. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at below 25°C: keep in the original container, protect from moisture and light.

Irbesartan-Comp Puren may interact with several medicines. Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade can increase renal risk. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - NSAIDs: may blunt antihypertensive effect and impair renal function. - Lithium: increased lithium concentrations and toxicity. Moderate Interactions (Monitor Closely): - ACE inhibitors: additive blood‑pressure lowering, monitor for hypotension. - Other antihypertensives: dose adjustments may be required. - CYP2C9 inhibitors (e.g., amiodarone): may raise irbesartan levels. - CYP3A4 inhibitors (e.g., clarithromycin): may increase exposure to irbesartan.